Omega-3 fish oil
Content updated · how dates work
Strong human evidenceIn the same VITAL trial, daily marine omega-3 did not significantly reduce major heart events or cancer, although heart attacks were lower in a secondary analysis.
Also called: Fish oil, EPA, DHA, Marine n-3 fatty acids
Featured study
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer ↗
The New England journal of medicine · 2019 · PMID 30415637
- Who was studied
- 25,871 U.S. men aged 50 and older and women aged 55 and older at usual risk, followed for a median of 5.3 years.
- How
- Randomized, placebo-controlled two-by-two factorial trial of marine omega-3 fatty acids and vitamin D3 for primary prevention.
- What it found
- Omega-3 did not significantly lower the main composite of heart attack, stroke or cardiovascular death (hazard ratio 0.92) or invasive cancer (1.03). In a secondary analysis, total heart attacks were lower (0.72); stroke and cardiovascular deaths were not.
- Limits
- A secondary finding such as fewer heart attacks needs confirmation, because many secondary outcomes were tested. The trial studied people at usual risk, so it does not speak to high-risk patients or prescription omega-3 drugs.
Safety & what remains unknown
No excess bleeding or serious adverse events were seen in VITAL. People taking blood thinners, or with fish or shellfish allergy, should check with a clinician; some studies of higher intakes have linked omega-3 to atrial fibrillation.
Talk to a clinician before starting a supplement, especially if you are pregnant, take prescription medicines or have a medical condition.
Where to find it
Seller lab-report checks and prices are available to members. Sign up free
For research and education only. This page does not provide medical advice, diagnosis, or treatment, and is not a recommendation to use any product.
See something wrong on this page? Report a mistake · Corrections